Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting

OBJECTIVE
The current standard for hospital glucose management is point-of-care (POC) testing. We conducted a randomized controlled trial of real-time continuous glucose monitoring (RT-CGM) compared with POC in a non-intensive care unit (ICU) hospital setting.

RESEARCH DESIGN AND METHODS
A total of 110 adults with type 2 diabetes on a non-ICU floor received RT-CGM with Dexcom G6 versus usual care (UC). RT-CGM data were wirelessly transmitted from the bedside. Hospital telemetry monitored RT-CGM data and notified bedside nursing of glucose alerts and trends. Standardized protocols were used for interventions.

RESULTS
The RT-CGM group demonstrated significantly lower mean glucose (Δ52 = −18.5 mg/dL) and percentage of time in hyperglycemia (>250 mg/dL (−11.41%) and higher time in range 70–250 mg/dL (+11.26%) compared with UC (P values <0.05). Percentage of time in hypoglycemia was very low.

CONCLUSIONS
RT-CGM can be used successfully in community-based hospital non-ICU settings to improve glucose management. Continuously streaming glucose readings may truly be the fifth vital sign.
functions for sharing and monitoring; need for additional equipment (mobile phones), Bluetooth transmission capability, and information services support for glucose data transmission; and, possibly most importantly, a lack of consensus, training, and protocols on how to best use the enormous amount of streaming glucose data that will now be available for glycemic management. Additionally, a number of significant potential confounders exist in the hospital setting (i.e., medications, procedures, renal function, hepatic function, and acute illness), all of which can potentially impact the validity of CGM.

Finally, there is a lack of randomized controlled trials (RCTs) of real-time CGM (RT-CGM) compared with POC in hospital settings that might provide guidance on CGM implementation in this environment. This report is a subset of a larger, statistically powered (N = 404) RCT (NCT03068273) being conducted at two large hospitals in San Diego (Scripps Health). However, due to the current coronavirus disease 2019 (COVID-19) pandemic, we felt compelled to analyze this subset of Dexcom G6 CGM (San Diego, CA) users to provide data to hospital systems that are implementing Dexcom G6.

RESEARCH DESIGN AND METHODS

A total of 110 adults ≥18 years old, Spanish or English speaking, with type 2 diabetes (T2D) and three POC or serum values >200 mg/dL in the last 24 h, requiring subcutaneous insulin, were admitted to a non-intensive care unit (ICU) floor at Scripps Mercy Hospital (San Diego, CA) and enrolled in an RCT for ≥18 h. Pregnancy, intravenous insulin, adhesive allergy, anticipated computed tomography/MRI/diathermy procedures in next 24 h, or any condition deemed contraindicated were reasons for exclusion. The Scripps Health Institutional Review Board (San Diego, CA) approved the study.

After informed consent, enrollment, and randomization, a Dexcom G6 was placed by a research assistant or nurse. Blinded CGM data were used for evaluation only in usual care (UC) (standard POC testing protocol; n = 53). Data in the RT-CGM group (n = 57) were wirelessly transmitted from a bedside smartphone to secure Health Insurance Portability and Accountability Act–compliant, monitoring platforms: Dexcom FOLLOW and CLARITY (Supplementary Fig. 1A). To target a hospital time in range (TIR) of 70–250 mg/dL, hospital telemetry monitored RT-CGM data in FOLLOW on an iPad and notified nursing of hyperglycemia (>250 mg/dL, 9:00 p.m.–4:00 a.m.) and trends toward hypoglycemia (<90 mg/dL, 24 h/day) for rapid treatment per protocol (Real-Time Adjustments, Supplementary Fig. 1B0). Of note, because CGM was not U.S. Food and Drug Administration–approved for hospital use, confirmatory POC testing was conducted before treatment, and RT-CGM participants were still monitored via the hospital’s standard POC protocol (~4 times/day). All previous anti-hyperglycemic agents were discontinued, and participants were placed on the hospital subcutaneous insulin protocol to standardize glucose management across groups. A diabetes advanced practice nurse conducted the POC review for all participants and remotely monitored CGM trends in CLARITY and collaborated with hospitalists to make standardized algorithm-based insulin adjustments using trends noted to optimize therapy in the RT-CGM only (Daily Adjustments, Supplementary Fig. 1Bb).

Baseline characteristics were examined to evaluate randomization using χ², t, and Mann-Whitney tests. Restricted maximum likelihood was used in a linear effects model (11) to evaluate concordance between CGM and POC values. Participant-level CGM metrics included CGM duration, glucose mean, SD, and coefficient of variation, and percentage of TIR (70–180, 70–250, 70–250 mg/dL) and time in hyperglycemia (>250, 300 mg/dL) and hypoglycemia (<70, 54 mg/dL). Outcomes were tested in unadjusted linear regression models with group as a fixed effect, unless otherwise specified. Results reported in the text are regression coefficients (β) for the group effect and represent expected mean differences between RT-CGM (coded 1) and UC (coded 0). Hypoglycemic events (≥20 min <54 or 70 mg/dL) were descriptively analyzed to document the number of participants with one or more event and the number/participant and event duration. All analyses were conducted in R 3.5.3 software.

RESULTS

Participants ranged from 30 to 89 years old (mean 61.94 [SD 13.22]); most were women (54.5%) and Hispanic (74.3%). No significant between-group differences were observed in baseline characteristics, CGM duration, use of glucose-affecting medications during the hospitalization, or length of stay (P values >0.31). CGM values obtained within 5 min of POC were highly predictive of the POC value (P < 0.001). Respectively, marginal and conditional R² = 0.76 and 0.83 for the entire course of CGM data, and R² = 0.77 and 0.84 with removal of the initial 6 h of CGM data postsensor insertion. There were no qualifying adverse events.

Analysis of CGM outcomes showed the RT-CGM group demonstrated significantly lower mean glucose (β = −18.5) and percentage of time in hyperglycemia >250 mg/dL (β = −11.41) and higher TIR 70–250 mg/dL (β = 11.26) compared with UC (P values <0.05). Percentage of time in hyperglycemia >250 mg/dL was inversely correlated with TIR 70–250 mg/dL (r = −0.99, P < 0.0001). The RT-CGM group also exhibited trends toward a lower percentage of time in hyperglycemia >300 mg/dL (β = −7.05) and higher TIR 70–200 mg/dL (β = 9.14) compared with UC (P values <0.07). There were no between-group differences in TIR 70–180 mg/dL or glucose variability (P values >0.14).

Percentage of time in hypoglycemia <70 and ≤54 mg/dL was very low and did not differ significantly between groups (all medians = 0; P values >0.26). An examination of hypoglycemic events <70 and ≤54 mg/dL revealed a slightly greater number experiencing one or more hypoglycemic event(s) in the RT-CGM group. However, descriptive analyses conducted among those who experienced one or more hypoglycemic event(s) showed that the median number of events per person was lower in the RT-CGM versus the UC group for hypoglycemia <70 mg/dL (1.0 vs. 2.0) and <54 mg/dL (1.0 vs. 3.5). Further, the median duration of these events was 50.00 and 7.41 min shorter in the RT-CGM group for hypoglycemia <70 and <54 mg/dL, respectively.

The RT-CGM group also exhibited significantly lower mean POC glucose (P = 0.01); however, there were no statistically significant differences in average daily insulin dosing by group (P values >0.90). All findings are further detailed in Table 1.

CONCLUSIONS

This was the first RCT to compare the effectiveness of RT-CGM versus standard hospital glucose management in a non-ICU hospital setting. Our data demonstrate that RT-CGM and standardized protocols for the RT management of acute hyper-/hypoglycemia improved mean glucose and TIR without increasing
Table 1—Demographics and results

| Demographics                                      | UC (n = 53) | RT-CGM (n = 57) | P value |
|---------------------------------------------------|-------------|-----------------|---------|
| **Baseline demographics**                         |             |                 |         |
| Age, mean (SD)                                    | 60.94 (12.37)| 62.88 (14.01)   | 0.5946  |
| Male, n (%)                                       | 23 (43.4)   | 27 (47.4)       | 0.6759  |
| Hispanic, n (%)                                   | 42 (80.8)   | 39 (68.4)       | 0.5620  |
| T2D duration, years, mean (SD)                    | 18.51 (12.04)| 16.23 (9.74)    | 0.5653  |
| **Clinical characteristics at admission**         |             |                 |         |
| Haemoglobin, %                                    | 8.65 (7.68–10.53)| 9.5 (7.6–11.1)  | 0.7957  |
| POC, mg/dL                                        | 245.5 (196.5–298.25)| 261 (213–315)  | 0.7957  |
| Serum creatinine, mg/dL                           | 1.00 (0.70–1.90)| 1.00 (0.60–2.10)| 0.7956  |
| Hematocrit, %, mean (SD)                          | 36.42 (6.08) | 36.11 (7.02)    | 0.8012  |
| eGFR, mL/min/1.73 m², n (%)                       | <30: 15 (28.3) | 17 (29.8)       | 0.8012  |
|                                                     | 30–45: 6 (11.3) | 5 (8.8)         |         |
|                                                     | 46–60: 3 (5.7)  | 1 (1.8)         |         |
|                                                     | >60: 29 (54.7)  | 34 (59.7)       |         |
| BMI, kg/m²                                        | 30.65 (25.27–36.20)| 29.9 (25.02–33.40)| 0.7957 |
| **Hospitalization statistics**                    |             |                 |         |
| Length of stay, days                              | 5.0 (3.0–9.0) | 5.0 (3.0–8.0)   | 0.9880  |
| Glucose-impacting medications, n (%)              |             |                 |         |
| Steroids                                          | 14 (26.4)   | 16 (28.1)       | 0.9490  |
| Psychotropicans                                    | 11 (20.8)   | 5 (8.8)         | 0.6545  |
| Quinolones                                        | 6 (11.3)    | 3 (5.3)         | 0.8360  |
| Dextrose-containing fluids                         | 19 (35.9)   | 24 (42.1)       | 0.8360  |
| Other                                             | 2 (3.8)     | 1 (1.8)         | 0.9490  |
| Insulin dosing, units/kg/day                       | 0.25 (0.16–0.34)| 0.26 (0.19–0.32)| 0.9094 |
|                   Long-acting                          | 0.31 (0.20–0.40)| 0.26 (0.18–0.36)| 0.9094 |
|                   Rapid-acting                          | 0.50 (0.31–0.70)| 0.53 (0.33–0.64)| 0.9094 |
| **Glucose outcomes**                              |             |                 |         |
| POC, mg/dL, mean (SD)                             | 212.40 (45.91)| 191.50 (38.89)  | 0.0115  |
| CGM                                               |             |                 |         |
| CGM duration, h                                    | 47.75 (25.92–80.42)| 51.00 (25.33–96.25) | 0.8091 |
| Mean glucose, mg/dL, mean (SD)                    | 238.05 (45.26)| 219.51 (43.75)  | 0.0311  |
| SD glucose, mg/dL, mean (SD)                      | 57.16 (19.44)| 54.58 (16.94)   | 0.7041  |
| CV glucose, mg/dL, mean (SD)                      | 24.78 (9.20) | 25.41 (8.07)    | 0.7041  |
| % TIR                                            |             |                 |         |
| 70–180 mg/dL                                      | 19.89 (3.34–40.09)| 25.31 (11.78–42.97) | 0.1460 |
| 70–200 mg/dL                                      | 33.38 (10.90–55.74)| 42.82 (25.66–58.53) | 0.0615 |
| 70–250 mg/dL                                      | 63.95 (31.25–77.95)| 72.83 (59.03–83.57) | 0.0404 |
| % Hyperglycemia                                   |             |                 |         |
| >250 mg/dL                                        | 32.96 (20.40–68.75)| 27.00 (16.01–40.97) | 0.0403 |
| >300 mg/dL                                        | 13.10 (2.90–39.40)| 7.33 (2.03–18.54) | 0.0512  |
| % Hypoglycemia                                    |             |                 |         |
| <70 mg/dL                                         | 0.00 (0.00–0.00)| 0.00 (0.00–0.00) | 0.2680  |
| <54 mg/dL                                         | 0.00 (0.00–0.00)| 0.00 (0.00–0.00) | 0.8093  |
| Hypoglycemic event(s) N (%) with ≤1 event(s)      |             |                 |         |
| <70 mg/dL                                         | 5 (9.43)    | 11 (19.3)       |         |
| <54 mg/dL                                         | 2 (3.77)    | 4 (7.02)        |         |

Continued on p. 2876
An RCT of CGM in a Non-ICU Hospital Setting

Diabetes Care Volume 43, November 2020

Patients tolerated the device well, without complaints of sleep interruption or discomfort. Sensor and/or transmitter issues, sensor detachment, and persistent sensor signal loss were extremely rare, and very few sensors were wasted. More common was (temporary) transmission loss when patients transferred out of the room for procedures. However, if the device remained in place during a procedure, data were captured retrospectively without gaps when the patients returned to their rooms and were within 20 feet of the study phone. Currently, there are restrictions to keeping the transmitter on during certain procedures such as MRI, computed tomography, and surgical procedures using diathermy (10). Although some early reports with devices not placed on patients indicated accuracy (17), more research is needed to indicate whether they can remain on during these procedures.

The low occurrence of hypoglycemia precluded statistical testing for differences in the number and duration of these events. However, descriptives clearly showed beneficial trends of RT-CGM. Future consideration might be given to intervening earlier—at higher thresholds than those used here for nurse notification (<90 mg/dL) and treatment (<80 mg/dL)—to further improve the prevention of hypoglycemic events. While this study selected participants based on observed hyperglycemia, future studies should consider adding high risk for hypoglycemia as inclusion criteria. This study did not treat directly from CGM readings, although trends were used for adjustments, but it would be valuable to evaluate this approach.

Finally, the cost-to-benefit ratio must be considered because this could preclude use more broadly. Clearly, increased costs stem from having a CGM support team in place as well as the cost of the devices themselves. Although this may be offset by the fact that the cost of CGM is continuously declining, and despite average use of sensors in our study of 2 days, lengthening CGM placement time could ensue by allowing continued wear during currently restricted procedures (10). A final cost analysis will be conducted once the full study is completed, but further financial benefits could be accrued if improved glucose control lowers overall length of stay, infections, and other hospital costs. Additionally, we know that people with diabetes have higher rates of readmission (18, 19), and if the CGM could be continued during the transition to the immediate postdischarge period, there may be further benefit in preventing readmissions.

In conclusion, RT-CGM can be used safely and successfully in community-based hospital settings to improve glucose management. The definition of a vital sign is a clinical measurement that indicates the state of a body’s essential function. Maintaining metabolic and glucose equilibrium is part of that essential function, and now, with the ability to continuously stream glucose readings, this may truly be the fifth vital sign.

Acknowledgments. The authors would like to extend their sincere thanks to their research team, including Teresa Vela, Ioanna Loupas, Andrea Jimenez, Kimberly Luu, Alessandra Bastian, and Renny Babanatos (Scripps Whittier Diabetes Institute, San Diego, CA) for their dedication in the conduct of this trial. Additionally, the authors would like to thank and acknowledge the support of the telemetry team, the hospitalist groups, and the Scripps Mercy Hospital Leadership Team for their support on the implementation and execution of the study. The authors sincerely thank all the participants in the study.

Funding. Funding to support the research has been received from the Center for Advancing Translational Sciences (UL1 TR002550-01). Dexcom provided the G6 devices.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

| Table 1—Continued |
|------------------|
| | UC (n = 53) | RT-CGM (n = 57) | P value |
| Number of events<sup>a</sup> | | | |
| <70 mg/dL | 2.00 (1.00–4.00) | 1.00 (1.00–1.50) | |
| <54 mg/dL | 3.50 (2.75–4.25) | 1.00 (1.00–2.25) | |
| Duration of events<sup>a</sup> | | | |
| <70 mg/dL | | | |
| Number of readings | 19.00 (15.00–20.25) | 9.00 (7.50–11.00) | |
| Time, in min | 95.00 (75.00–101.25) | 45.00 (37.50–55.00) | |
| <54 mg/dL | | | |
| Number of readings | 9.40 (7.20–11.60) | 7.92 (7.38–12) | |
| Time, in min | 47.00 (36.00–58.00) | 39.59 (36.88–60) | |

Data are median (interquartile range) unless otherwise specified. All reported P values are two-sided. Multiple comparisons within outcomes were accounted for using the false-discovery rate adjustment. CV, coefficient of variation. *As a result of missing data at admission, the following represent the sample sizes for each: Hispanic (n = 52, 57), T2D duration (n = 51, 56), HbA1c (n = 44, 49), POC (n = 52, 55), and BMI (n = 48, 56), in UC and RT-CGM, respectively. Statistics reflect the n (%) of participants who were administered the glucose-affecting medication at any time during the hospitalization. #Reported P values are derived from unadjusted linear regression models for each outcome with group as a fixed effect, except for both % hypoglycemia measures, which were derived from Mann-Whitney U tests due to skewed distribution. #Defined as four or more consecutive values below respective threshold. & As a result of the low frequency of events in the overall sample, data are presented for participants with one or more hypoglycemic event. P values are not presented due to small n in these subanalyses.

Data to recommend widespread use of CGM in hospitalized patients (15). The COVID-19 pandemic has accelerated the need to identify safe methods to monitor glucose in the hospital yet allow ongoing and effective interventions. Our RCT provides preliminary evidence of the value of CGM in a non-ICU environment and offers opportunities to share device implementation practices, standardized protocols, and team-based models that use existing staff (diabetes advanced practice nurse, bedside nurses, and telemetry) to manage glucose. Because hospitalists and bedside nurses were often unfamiliar with CGM, having our study team place devices, establish data transmission, and monitor/encourage adherence to alert protocols was valuable and alleviated burden for busy bedside nurses. We would like to emphasize the importance of having access to an inpatient diabetes team. CGM cannot be successfully deployed without dedicated diabetes-minded staff to help oversee the platform and educate frontline staff about its use.

Diabetes prevalence is higher in regions with high rates of ethnic/racial minority populations—groups that experience disproportionately higher rates of diabetes-related complications (16). This study, undertaken in a hospital near the U.S.-Mexico border, included 80% Hispanic patients and demonstrated successful outcomes for this high-risk population.
Author Contributions. A.L.F., S.R.S.B., L.T., I.M.G., H.S., A.H., and A.P.-T. participated in the design and execution of the study, in the review of the data, and in the writing and review of the manuscript. A.P.-T. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented in abstract form at the 77th Scientific Sessions of the American Diabetes Association, San Diego, CA, 9–13 June 2017.

References

1. Murad MH, Coburn JA, Coto-Yglesias F, et al. Glycemic control in non-critically ill hospitalized patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012;97:49–58
2. Kyi M, Colman PG, Wraight PR, et al. Early intervention for diabetes in medical and surgical inpatients decreases hyperglycemia and hospital-acquired infections: a cluster randomized trial. Diabetes Care 2019;42:832–840
3. Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 2014;63:1738–1747
4. Bersoux S, Cook CB, Kongable GL, Shu J, Zito DR. Benchmarking glycemic control in U.S. hospitals. Endocr Pract 2014;20:876–883
5. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34:256–261
6. Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30:2181–2186
7. Varghese P, Gleason V, Sorokin R, Senholzi C, Jabbour S, Gottlieb JE. Hypoglycemia in hospitalized patients treated with antihyperglycemic agents. J Hosp Med 2007;2:234–240
8. Burt MG, Roberts GW, Aguilar-Loza NR, Stranks SN. Brief report: comparison of continuous glucose monitoring and finger-prick blood glucose levels in hospitalized patients administered basal-bolus insulin. Diabetes Technol Ther 2013;15:241–245
9. Gómez AM, Umpierrez GE, Muñoz OM, et al. Continuous glucose monitoring versus capillary point-of-care testing for inpatient glycemic control in type 2 diabetes patients hospitalized in the general ward and treated with a basal bolus insulin regimen. J Diabetes Sci Technol 2015;10:325–329
10. Wallia A, Umpierrez GE, Rushakoff RJ, et al.; DTS Continuous Glucose Monitoring in the Hospital Panel. Consensus statement on inpatient use of continuous glucose monitoring. J Diabetes Sci Technol 2017;11:1036–1044
11. Nakagawa S, Schielzeth H. A general and simple method for obtaining R² from generalized linear mixed-effects models. Methods Ecol Evol 2013;4:133–142
12. Umpierrez GE, Klonoff DC. Diabetes technology update: use of insulin pumps and continuous glucose monitoring in the hospital. Diabetes Care 2018;41:1579–1589
13. Levitt DL, Silver KD, Spanakis EK. Mitigating severe hypoglycemia by initiating inpatient continuous glucose monitoring for type 1 diabetes mellitus. J Diabetes Sci Technol 2017;11:440–441
14. Spanakis EK, Levitt DL, Siddiqui T, et al. The effect of continuous glucose monitoring in preventing inpatient hypoglycemia in general wards: the glucose telemetry system. J Diabetes Sci Technol 2018;12:20–25
15. American Diabetes Association. 15. Diabetes care in the hospital: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S193–S202
16. Chow EA, Foster H, Gonzalez V, McIver L. The disparate impact of diabetes on racial/ethnic minority populations. Clin Diabetes 2012;30:130–133
17. Thomas C, Welsh JB, Lu S, Gray JM. Safety and functional integrity of continuous glucose monitoring components after simulated radiologic procedures. J Diabetes Sci Technol. 22 April 2020 [Epub ahead of print]. DOI: 10.1177/1932296820920948
18. Rubin DJ. Hospital readmission of patients with diabetes. Curr Diab Rep 2015;15:17
19. McCoy RG, Lipska KJ, Herrin J, Jeffery MM, Krumholz HM, Shah ND. Hospital readmissions among commercially insured and Medicare Advantage beneficiaries with diabetes and the impact of severe hypoglycemic and hyperglycemic events. J Gen Intern Med 2017;32:1097–1105